Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis

1 September 2024 (14:00 - 14:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Mr Bryan Tan

Singapore (Singapore)

8 More presentations in this session

Presentation thumbnail

The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank

Doctor T. Guo (Xi'an, CN)

Abstract Slides Video

Presentation thumbnail

The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.

Doctor S. Maragkoudakis (Chania, GR)

Abstract Slides Video

Presentation thumbnail

All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries

Doctor P. Yazdanfard (Hilleroed, DK)

Abstract Slides Video

Presentation thumbnail

Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.

Doctor M. Feola (Mondovi, IT)

Abstract Slides Video

Presentation thumbnail

Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service

Mr S. Mcbrien (Belfast, GB)

Abstract Slides Video

Access the full session

Session thumbnail

Real-world evidence on the cardiovascular effects of therapies for diabetes

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET

You may be interested in

Congress Presentation

The next decade in the treatment of obesity

Congress Presentation

GIP and GLP-1 agonists for obesity

Congress Presentation

Anti-obesity medications: cardiovascular benefits and new perspectives beyond weight loss

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources